Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics

References

• Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov. 2008;7(1):21–29. doi:10.1038/nrd2399. PMID: 18097458.
   PubMed Web of Science ®Google Scholar
• Alt N, Zhang TY, Motchnik P, Taticek R, Quarmby V, Schlothauer T, Beck H, Emrich T, Harris RJ. Determination of critical quality attributes for monoclonal antibodies using quality by design principles. Biolog. 2016;44(5):291–305. doi:10.1016/j.biologicals.2016.06.005. PMID: 27461239.
   Google Scholar
• Kaplon H, Chenoweth A, Crescioli S, Reichert JM. Antibodies to watch in 2022. Mabs. 2022;14(1):2014296. doi:10.1080/19420862.2021.2014296. PMID: 35030985.
   PubMed Web of Science ®Google Scholar
• Kaplon H, Reichert JM. Antibodies to watch in 2021. Mabs. 2021;13(1):1860476. doi:10.1080/19420862.2020.1860476. PMID: 33459118.
   PubMed Web of Science ®Google Scholar
• Kinch MS, Kraft Z, Schwartz T. Monoclonal antibodies: trends in therapeutic success and commercial focus. Drug Discov Today. 2023;28(1):103415. doi:10.1016/j.drudis.2022.103415. PMID: 36280042.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Chakraborti S, He Y, Roberts A, Sheahan T, Xiao X, Hensley LE, Prabakaran P, Rockx B, Sidorov IA, et al. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc National Acad Sci. 2007;104(29):12123–28. doi:10.1073/pnas.0701000104. PMID: 17620608.
   PubMed Web of Science ®Google Scholar
• Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, Vachieri SG, Pinna D, Minola A, Vanzetta F, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza a hemagglutinins. Sci. 2011;333(6044):850–56. doi:10.1126/science.1205669. PMID: 21798894.
   PubMed Web of Science ®Google Scholar
• Stettler K, Beltramello M, Espinosa DA, Graham V, Cassotta A, Bianchi S, Vanzetta F, Minola A, Jaconi S, Mele F, et al. Specificity, cross-reactivity, and function of antibodies elicited by zika virus infection. Sci. 2016;353(6301):823–26. doi:10.1126/science.aaf8505. PMID: 27417494.
   PubMed Web of Science ®Google Scholar
• Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, Wu HC. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27:1. doi:10.1186/s12929-019-0592-z. PMID: 31894001.
   PubMed Web of Science ®Google Scholar
• Xu J, Ou J, McHugh KP, Borys MC, Khetan A. Upstream cell culture process characterization and in-process control strategy development at pandemic speed. Mabs. 2022;14(1):2060724. doi:10.1080/19420862.2022.2060724. PMID: 35380922.
   PubMed Web of Science ®Google Scholar
• Pecetta S, Finco O, Seubert A. Quantum leap of monoclonal antibody (mAb) discovery and development in the COVID-19 era. Semin Immunol. 2020;50:101427–101427. doi:10.1016/j.smim.2020.101427. PMID: 33277154.
   PubMed Web of Science ®Google Scholar
• Kelley B. Developing therapeutic monoclonal antibodies at pandemic pace. Nat Biotechnol. 2020;38(5):540–45. doi:10.1038/s41587-020-0512-5. PMID: 32317764.
   PubMed Web of Science ®Google Scholar
• Khetan R, Curtis R, Deane CM, Hadsund JT, Kar U, Krawczyk K, Kuroda D, Robinson SA, Sormanni P, Tsumoto K, et al. Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics. Mabs. 2022;14(1):2020082. doi:10.1080/19420862.2021.2020082. PMID: 35104168.
   PubMed Web of Science ®Google Scholar
• Farid SS, Baron M, Stamatis C, Nie W, Coffman J. Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D. Mabs. 2020;12(1):1754999. doi:10.1080/19420862.2020.1754999. PMID: 32449439.
   PubMed Web of Science ®Google Scholar
• La Merie Publishing. 2021 sales of recombinant therapeutic antibodies, proteins, biosimilars & other biologics; 2022. http://www.lamerie.com.
   Google Scholar
• Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov. 2007;6(5):349–56. doi:10.1038/nrd2241. PMID: 17431406.
   PubMed Web of Science ®Google Scholar
• Pavlou AK, Belsey MJ. The therapeutic antibodies market to 2008. Eur J Pharm Biopharm. 2005;59(3):389–96. doi:10.1016/j.ejpb.2004.11.007. PMID: 15760719.
   PubMed Web of Science ®Google Scholar
• Presta LG. Selection, design, and engineering of therapeutic antibodies. J Allergy Clin Immun. 2005;116(4):731–36. doi:10.1016/j.jaci.2005.08.003. PMID: 16210043.
   PubMed Web of Science ®Google Scholar
• McNeil C. Monoclonal antibodies to watch. Jnci J National Cancer Inst. 1995;87(22): 1659–1659. doi:10.1093/jnci/87.22.1659.
   Web of Science ®Google Scholar
• Maggon K. Monoclonal antibody “gold rush. Curr Med Chem. 2007;14(18):1978–87. doi:10.2174/092986707781368504. PMID: 17691940.
   PubMed Web of Science ®Google Scholar
• Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. Mabs. 2015;7(1):9–14. doi:10.4161/19420862.2015.989042. PMID: 25529996.
   PubMed Web of Science ®Google Scholar
• Cui Y, Cui P, Chen B, Li S, Guan H. Monoclonal antibodies: formulations of marketed products and recent advances in novel delivery system. Drug Dev Ind Pharm. 2017;43(4):1–39. doi:10.1080/03639045.2017.1278768. PMID: 28049357.
   PubMed Web of Science ®Google Scholar
• Wilkinson I, Hale G. Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names. Mabs. 2022;14(1):2123299. doi:10.1080/19420862.2022.2123299. PMID: 36109838.
   PubMed Web of Science ®Google Scholar
• Li F, Vijayasankaran N, Shen A, Kiss R, Amanullah A. Cell culture processes for monoclonal antibody production. Mabs. 2014;2(5):466–79. doi:10.4161/mabs.2.5.12720. PMID: 20622510.
   Google Scholar
• Raju TS, Jordan RE. Galactosylation variations in marketed therapeutic antibodies. Mabs. 2012;4(3): 310–309. doi:10.4161/mabs.19868. PMID: 22531450.
   Web of Science ®Google Scholar
• Singh SK. Impact of product‐related factors on immunogenicity of biotherapeutics. J Pharm Sci. 2011;100(2):354–87. doi:10.1002/jps.22276. PMID: 20740683.
   PubMed Web of Science ®Google Scholar
• Jain T, Sun T, Durand S, Hall A, Houston NR, Nett JH, Sharkey B, Bobrowicz B, Caffry I, Yu Y, et al. Biophysical properties of the clinical-stage antibody landscape. Proc National Acad Sci. 2017;114(5):944–49. doi:10.1073/pnas.1616408114. PMID: 28096333.
   PubMed Web of Science ®Google Scholar
• Strohl WR. Current progress in innovative engineered antibodies. Protein Cell. 2018;9(1):86–120. doi:10.1007/s13238-017-0457-8. PMID: 28822103.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2010. Mabs. 2010;2(1):84–100. doi:10.4161/mabs.2.1.10677. PMID: 20065640.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibody-based therapeutics to watch in 2011. Mabs. 2011;3(1):76–99. doi:10.4161/mabs.3.1.13895. PMID: 21051951.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Which are the antibodies to watch in 2012? Mabs. 2012;4(1):1–3. doi:10.4161/mabs.4.1.18719. PMID: 22327425.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Which are the antibodies to watch in 2013? Mabs. 2013;5(1):1–4. doi:10.4161/mabs.22976. PMID: 23254906.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2013. Mabs. 2013;5(4):513–17. doi:10.4161/mabs.24990. PMID: 23727858.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2014. Mabs. 2013;6(1):5–14. doi:10.4161/mabs.27333. PMID: 24284914.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2014. Mabs. 2014;6(4):799–802. doi:10.4161/mabs.29282. PMID: 24846335.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2015. Mabs. 2015;7(1):1–8. doi:10.4161/19420862.2015.988944. PMID: 25484055.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2016. Mabs. 2015;8(2):197–204. doi:10.1080/19420862.2015.1125583. PMID: 26651519.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2017. Mabs. 2017;9(2): 00–00. doi:10.1080/19420862.2016.1269580. PMID: 27960628.
   PubMed Web of Science ®Google Scholar
• Kaplon H, Reichert JM. Antibodies to watch in 2018. Mabs. 2018;10(2): 00–00. doi:10.1080/19420862.2018.1415671. PMID: 29300693.
   PubMed Web of Science ®Google Scholar
• Kaplon H, Reichert JM. Antibodies to watch in 2019. Mabs. 2018;11(2):219–38. doi:10.1080/19420862.2018.1556465. PMID: 30516432.
   PubMed Web of Science ®Google Scholar
• Kaplon H, Muralidharan M, Schneider Z, Reichert JM. Antibodies to watch in 2020. Mabs. 2019;12(1):1703531. doi:10.1080/19420862.2019.1703531. PMID: 31847708.
   Web of Science ®Google Scholar
• Kaur H. Characterization of glycosylation in monoclonal antibodies and its importance in therapeutic antibody development. Crit Rev Biotechnol. 2021;41(2):300–15. doi:10.1080/07388551.2020.1869684. PMID: 33430641.
   PubMed Web of Science ®Google Scholar
• Kaur H. Stability testing in monoclonal antibodies. Crit Rev Biotechnol. 2021;41(5):692–714. doi:10.1080/07388551.2021.1874281. PMID: 33596751.
   PubMed Web of Science ®Google Scholar
• Lai Y, Suo S, Wang R, Kong X, Hu Y, Tang D, Shi H, Chen S, Hu H. Trends involving monoclonal antibody (mAb) research and commercialization: a scientometric analysis of IMS lifecycle R&D focus database (1980–2016). Hum Vacc Immunother. 2018;14(4): 00–00. doi:10.1080/21645515.2017.1420445. PMID: 29293380.
   Web of Science ®Google Scholar
• Abd YE, Tabll A, Smolic R, Smolic M. Mini-review: the market growth of diagnostic and therapeutic monoclonal antibodies – SARS CoV-2 as an example. Hum Antibodies. 2022;30(1):15–24. doi:10.3233/hab-211513. PMID: 34958012.
   PubMedGoogle Scholar
• Focosi D, Tuccori M, Baj A, Maggi F. SARS-CoV-2 variants: a synopsis of in vitro efficacy data of convalescent plasma, currently marketed vaccines, and monoclonal antibodies. Viruses. 2021;13(7):1211. doi:10.3390/v13071211. PMID: 34201767.
   PubMed Web of Science ®Google Scholar
• Folkman R, Blennow O, Tovatt T, Pettersson K, Nowak P. Treatment of COVID-19 with monoclonal antibodies casirivimab and imdevimab in pregnancy. Infect. 2022;51(1):1–3. doi:10.1007/s15010-022-01829-4. PMID: 35482208.
   PubMed Web of Science ®Google Scholar
• Smith S. Ten years of orthoclone OKT3 (muromonab-CD3): a review. J Transpl Coordination. 1996;6(3):109–21. doi:10.7182/prtr.1.6.3.8145l3u185493182. PMID: 9188368.
   PubMedGoogle Scholar
• U.S. Food and Drug Administration (FDA). Drugs@FDA; 2022 [accessed 2022 Feb 8]. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm.
   Google Scholar
• European Medicines Agency (EMA). EMA medicines; 2022 [accessed 2022 Feb 8]. https://www.ema.europa.eu/en/medicines.
   Google Scholar
• World Health Organization (WHO). School of international nonproprietary names; 2022 [accessed 2022 Feb 8]. https://extranet.who.int/soinn/.
   Google Scholar
• World Health Organization (WHO). INN and biologicals; 2022 [accessed 2022 Feb 8]. https://www.who.int/teams/health-product-and-policy-standards/inn/inn-bio.
   Google Scholar
• Reichert JM. Marketed therapeutic antibodies compendium. Mabs. 2012;4(3):413–15. doi:10.4161/mabs.19931. PMID: 22531442.
   PubMed Web of Science ®Google Scholar
• Swan D, Loughran N, Makris M, Thachil J. Management of bleeding and procedures in patients on antiplatelet therapy. Blood Rev. 2020;39:100619. doi:10.1016/j.blre.2019.100619. PMID: 31648803.
   PubMed Web of Science ®Google Scholar
• Jayaraman K. Biocon’s first-in-class anti-CD6 mAb reaches the market. Nat Biotechnol. 2013;31(12):1062–63. doi:10.1038/nbt1213-1062b. PMID: 24316625.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan MS, Eswaraiah A, Crombet T, Piedra P, Saurez G, Iyer H, Arvind AS. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. Mabs. 2014;1(1):41–48. doi:10.4161/mabs.1.1.7509. PMID: 20046573.
   Google Scholar
• Centro para el Control Estatal de Medicamentos, Equipos y Dispositivos Médicos (CECMED). Resumen de las características del producto; 2020 [accessed 2022 Feb 9]. https://www.cecmed.cu/registro/rcp/biologicos/vaxirar-racotumomab.
   Google Scholar
• Administración Nacional de Medicamentos. Alimentos y tecnologia médica (ANMAT). Disposición 9016-16; 2016 [accessed 2022 Feb 9]. www.anmat.gov.ar/boletin_anmat/agosto_2016/Dispo_9016-16.pdf.
   Google Scholar
• Committee for Orphan Medicinal Products (COMP). Public summary of opinion on orphan designation Iodine (131I) tositumomab for the treatment of follicular lymphoma; 2015 [accessed 2022 Oct 25]. https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/03/136-public-summary-positive-opinion-orphan-designation-iodine-131i-tositumomab-treatment-follicular_en.pdf.
   Google Scholar
• European Medicines Agency (EMA). Refusal of the marketing authorisation for gamifant (emapalumab); 2020 [accessed 2022 Oct 25]. https://www.ema.europa.eu/en/documents/smop-initial/questions-answers-refusal-marketing-authorisation-gamifant-emapalumab_en.pdf.
   Google Scholar
• European Medicines Agency (EMA). European medicines agency decision; 2016 [accessed 2022 Oct 25]. https://www.ema.europa.eu/en/documents/pip-decision/p/0345/2016-ema-decision-2-december-2016-granting-product-specific-waiver-teprotumumab-emea-001973-pip01-16_en.pdf.
   Google Scholar
• Egger GF, Wharton GT, Malli S, Temeck J, Murphy MD, Tomasi P. A comparative review of waivers granted in pediatric drug development by FDA and EMA from 2007-2013. Ther Innov Regul Sci. 2016;50(5):639–47. doi:10.1177/2168479016646809. PMID: 27274951.
   PubMed Web of Science ®Google Scholar
• Mullard A. Drug withdrawal sends critical care specialists back to basics. Lancet. 2011;378(9805):1769. doi:10.1016/s0140-6736(11)61761-3. PMID: 22106464.
   PubMed Web of Science ®Google Scholar
• Viardot A, Bargou R. Bispecific antibodies in haematological malignancies. Cancer Treat Rev. 2018;65:87–95. doi:10.1016/j.ctrv.2018.04.002. PMID: 29635163.
   PubMed Web of Science ®Google Scholar
• Goldberg RM. Lessons learned from the edrecolomab story: how a checkered past became a checkered flag for monoclonal antibodies in colorectal cancer therapy. Oncol Res Treat. 2005;28(6–7):311–12. doi:10.1159/000085570. PMID: 15933417.
   Google Scholar
• World Health Organization (WHO). The use of stems in the selection of international nonproprietary names (INN) for pharmaceutical substances 2018; 2018 [accessed 2022 Feb 9]. https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-inn/stembook-2018.pdf
   Google Scholar
• Serafini M, Cargnin S, Massarotti A, Tron GC, Pirali T, Genazzani AA. What’s in a name? Drug nomenclature and medicinal chemistry trends using INN publications. J Med Chem. 2021;64(8):4410–29. doi:10.1021/acs.jmedchem.1c00181. PMID: 33847110.
   PubMed Web of Science ®Google Scholar
• Blaine L. The nomenclature of monoclonal antibodies. 1990. pp. 71–84. doi:10.1007/978-3-642-76011-2_8.
   Google Scholar
• World Health Organization (WHO). Guidelines on the use of international nonproprietary names for pharmaceutical substances; 1997 [accessed 2022 Sep 19]. http://whqlibdoc.who.int/hq/1997/WHO_PHARM_S_NOM_1570.pdf.
   Google Scholar
• World Health Organization (WHO). General policies for monoclonal antibodies; 2009 [accessed 2022 Feb 9]. https://www.who.int/medicines/services/inn/generalpoliciesmonoclonalantibodiesjan10.pdf.
   Google Scholar
• World Health Organization (WHO). Revised monoclonal antibody (mAb) nomenclature scheme; 2017 [accessed 2022 Feb 9]. https://www.who.int/medicines/services/inn/Revised_mAb_nomenclature_scheme.pdf.
   Google Scholar
• World Health Organization (WHO). New INN monoclonal antibody (mAb) nomenclature scheme; 2021 [accessed 2022 Jun 1]. https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-inn/new_mab_-nomenclature-_2021.pdf
   Google Scholar
• Koch SSG, Thorpe R, Kawasaki N, Lefranc MP, Malan S, Martin ACR, Mignot G, Plückthun A, Rizzi M, Shubat S, et al. International nonproprietary names for monoclonal antibodies: an evolving nomenclature system. Mabs. 2022;14(1):2075078. doi:10.1080/19420862.2022.2075078. PMID: 35584276.
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Pastan I. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res. 2011;17(20):6398–405. doi:10.1158/1078-0432.ccr-11-0487. PMID: 22003067.
   PubMed Web of Science ®Google Scholar
• McCombs JR, Owen SC. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry. Aaps J. 2015;17(2):339–51. doi:10.1208/s12248-014-9710-8. PMID: 25604608.
   PubMed Web of Science ®Google Scholar
• Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, et al. CAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458–65. doi:10.1182/blood-2003-01-0039. PMID: 12714494.
   PubMed Web of Science ®Google Scholar
• Younes A, Yasothan U, Kirkpatrick P. Brentuximab vedotin. Nat Rev Drug Discov. 2012;11(1):19–20. doi:10.1038/nrd3629. PMID: 22212672.
   PubMed Web of Science ®Google Scholar
• Fenton C, Perry CM. Gemtuzumab ozogamicin. Drugs. 2005;65(16):2405–27. doi:10.2165/00003495-200565160-00014. PMID: 16266206.
   PubMed Web of Science ®Google Scholar
• Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, Schilder RJ, Murray JL, Saleh M, Allen RS, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-hodgHodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood. 2002;99(12):4336–42. doi:10.1182/blood.v99.12.4336. PMID: 12036859.
   PubMed Web of Science ®Google Scholar
• Starodub AN, Ocean AJ, Shah MA, Guarino MJ, Picozzi VJ, Vahdat LT, Thomas SS, Govindan SV, Maliakal PP, Wegener WA, et al. First-in-human trial of a novel anti-trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors. Clin Cancer Res. 2015;21(17):3870–78. doi:10.1158/1078-0432.ccr-14-3321. PMID: 25944802.
   PubMed Web of Science ®Google Scholar
• Goel N, Stephens S. Certolizumab pegol. Mabs. 2010;2(2):137–47. doi:10.4161/mabs.2.2.11271. PMID: 20190560.
   PubMed Web of Science ®Google Scholar
• Blick SKA, Curran MP. Certolizumab pegol. Biodrugs. 2007;21(3):195–201. doi:10.2165/00063030-200721030-00006. PMID: 17516714.
   PubMed Web of Science ®Google Scholar
• Pasut G. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol. Biodrugs. 2014;28(S1):15–23. doi:10.1007/s40259-013-0064-z. PMID: 24687235.
   Google Scholar
• Ladwig PM, Barnidge DR, Willrich MAV. Quantification of the IgG2/4 kappa monoclonal therapeutic eculizumab from serum using isotype specific affinity purification and microflow LC-ESI-Q-TOF mass spectrometry. J Am Soc Mass Spectr. 2017;28(5):811–17. doi:10.1007/s13361-016-1566-y. PMID: 28004336.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). International nonproprietary names for pharmaceutical substances (INN): proposed INN: list 117; 2017 [accessed 2022 Sep 20]. https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl117.pdf.
   Google Scholar
• Bateman A, Martin MJ, Orchard S, Magrane M, Agivetova R, Ahmad S, Alpi E, Bowler-Barnett EH, Britto R, Bursteinas B, et al. UniProt: the universal protein knowledgebase in 2021. Nucleic Acids Res. 2020;49(D1):D480–9. doi:10.1093/nar/gkaa1100. PMID: 33237286.
   Web of Science ®Google Scholar
• Strohl WR, Ku Z, An Z, Carroll SF, Keyt BA, Strohl LM. Passive immunotherapy against SARS-CoV-2: from plasma-based therapy to single potent antibodies in the race to stay ahead of the variants. Biodrugs. 2022;36(3):231–323. doi:10.1007/s40259-022-00529-7. PMID: 35476216.
   PubMed Web of Science ®Google Scholar
• Aschenbrenner DS. New indications and approvals for anticancer drugs. Ajn Am J Nurs. 2021;121(12):16–17. doi:10.1097/01.naj.0000803180.17463.0b. PMID: 34792500.
   PubMed Web of Science ®Google Scholar
• Kim MS, Xu A, Haslam A, Prasad V. Quality of biomarker defined subgroups in FDA approvals of PD‐1/PD‐L1 inhibitors 2014 to 2020. Int J Cancer. 2022;150(11):1905–10. doi:10.1002/ijc.33968. PMID: 35182072.
   PubMed Web of Science ®Google Scholar
• Ahn S, Lee J, Shin DW, Kim J, Hwang JH. High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer. Sci Rep-Uk. 2020;10(1):12348. doi:10.1038/s41598-020-69366-4. PMID: 32704067.
   PubMed Web of Science ®Google Scholar
• Mo DC, Luo PH, Huang SX, Wang HL, Huang JF. Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: a systematic review. Int Immunopharmacol. 2021;91:107281. doi:10.1016/j.intimp.2020.107281. PMID: 33338862.
   PubMed Web of Science ®Google Scholar
• Qin Q, Li B. Pembrolizumab for the treatment of nonsmall cell lung cancer: current status and future directions. J Canc Res Ther. 2019;15(4):743. doi:10.4103/jcrt.jcrt_903_18. PMID: 31436226.
   PubMed Web of Science ®Google Scholar
• Neri P, Zucchi M, Allegri P, Lettieri M, Mariotti C, Giovannini A. Adalimumab (HumiraTM): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology. Int Ophthalmol. 2011;31(2):165–73. doi:10.1007/s10792-011-9430-3. PMID: 21287227.
   PubMedGoogle Scholar
• Patel T, Gordon KB. Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis. Dermatol Ther. 2004;17(5):427–31. doi:10.1111/j.1396-0296.2004.04045.x. PMID: 15379777.
   PubMedGoogle Scholar
• Alwawi EA, Mehlis SL, Gordon KB. Treating psoriasis with adalimumab. Ther Clin Risk Manag. 2008;4:345–51. doi:10.2147/tcrm.s1265. PMID: 18728850.
   PubMedGoogle Scholar
• Almagro JC, Fransson J. Humanization of antibodies. Frontiers Biosci J Virtual Libr. 2007;13:1619–33. doi:10.2741/2786. PMID: 17981654.
   Web of Science ®Google Scholar
• Vaswani SK, Hamilton RG. Humanized antibodies as potential therapeutic drugs. Ann Allergy Asthma Immunol. 1998;81(2):105–19. doi:10.1016/s1081-1206(10)62794-9. PMID: 9723555.
   PubMed Web of Science ®Google Scholar
• Rochere PDL, Guil-Luna S, Decaudin D, Azar G, Sidhu SS, Piaggio E. Humanized mice for the study of immuno-oncology. Trends Immunol. 2018;39(9):748–63. doi:10.1016/j.it.2018.07.001. PMID: 30077656.
   PubMed Web of Science ®Google Scholar
• Sgro C. Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review. Toxicol. 1995;105(1):23–29. doi:10.1016/0300-483x(95)03123-w. PMID: 8638282.
   PubMed Web of Science ®Google Scholar
• Clark M, Clark M. Antibody humanization: a case of the ‘emperor’s new clothes’? Immunol Today. 2000;21(8):397–402. doi:10.1016/s0167-5699(00)01680-7. PMID: 10916143.
   PubMedGoogle Scholar
• Hwang WYK, Foote J. Immunogenicity of engineered antibodies. Methods. 2005;36(1):3–10. doi:10.1016/j.ymeth.2005.01.001. PMID: 15848070.
   PubMed Web of Science ®Google Scholar
• Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biopharmaceuticals. Nephrol Dial Transpl. 2006;21(suppl_5):v9–12. doi:10.1093/ndt/gfl476. PMID: 16959792.
   PubMedGoogle Scholar
• U.S. Food and Drug Administration (FDA). Highlights of prescribing information (MYLOTARG); 2020 [accessed 2022 Oct 25]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761060s004lbl.pdf.
   Google Scholar
• Lee JE, Liu J, John C, Williams G, Rahman NA, Wang Y Clinical pharmacology and biopharmaceutics (Mylotarg); 2016 [accessed 2022 Oct 25]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761060Orig1s000Orig1Orig2s000ClinPharmR.pdf.
   Google Scholar
• European Medicines Agency (EMA). Guideline on immunogenicity assessment of therapeutic proteins; 2017. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf.
   Google Scholar
• U.S. Food and Drug Administration (FDA). Immunogenicity testing of therapeutic protein products — developing and validating assays for anti-drug antibody detection; 2019. https://www.fda.gov/media/119788/download.
   Google Scholar
• Pratt KP. Anti-drug antibodies: emerging approaches to predict, reduce or reverse biotherapeutic immunogenicity. Antibodies. 2018;7(2):19. doi:10.3390/antib7020019. PMID: 31544871.
   Web of Science ®Google Scholar
• Myler H, Pedras-Vasconcelos J, Phillips K, Hottenstein CS, Chamberlain P, Devanaryan V, Gleason C, Goodman J, Manning MS, Purushothama S, et al. Anti-drug antibody validation testing and reporting harmonization. Aaps J. 2021;24(1):4. doi:10.1208/s12248-021-00649-y. PMID: 34853961.
   PubMed Web of Science ®Google Scholar
• Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transpl. 2005;20(suppl_6):vi3–9. doi:10.1093/ndt/gfh1092. PMID: 15958824.
   PubMedGoogle Scholar
• Meis CM, Salzman EE, Maikawa CL, Smith AAA, Mann JL, Grosskopf AK, Appel EA. Self-assembled, dilution-responsive hydrogels for enhanced thermal stability of insulin biopharmaceuticals. Acs Biomater Sci Eng. 2021;7(9):4221–29. doi:10.1021/acsbiomaterials.0c01306. PMID: 34510910.
   PubMed Web of Science ®Google Scholar
• Buckley LA, Salunke S, Thompson K, Baer G, Fegley D, Turner MA. Challenges and strategies to facilitate formulation development of pediatric drug products: safety qualification of excipients. Int J Pharmaceut. 2018;536(2):563–69. doi:10.1016/j.ijpharm.2017.07.042. PMID: 28729174.
   PubMed Web of Science ®Google Scholar
• Pilunni D, Santuccio C, Sottosanti L, Felicetti P, Navarra P. Relationship between injection site reactions and different adalimumab formulations. Analysis of the adverse events reported in Italy in the period 2016-2019. Eur Rev Med Pharmaco. 2021;25:3300–05. doi:10.26355/eurrev_202104_25468. PMID: 33928613.
   PubMed Web of Science ®Google Scholar
• Yang YL, Lai TW. Citric acid in drug formulations causes pain by potentiating acid-sensing ion channel 1. J Neurosci. 2021;41(21):4596–606. doi:10.1523/jneurosci.2087-20.2021. PMID: 33888605.
   PubMed Web of Science ®Google Scholar
• Clair-Jones AS, Prignano F, Goncalves J, Paul M, Sewerin P. Understanding and minimising injection-site pain following subcutaneous administration of biologics: a narrative review. Rheumatology Ther. 2020;7(4):741–57. doi:10.1007/s40744-020-00245-0. PMID: 33206343.
   PubMed Web of Science ®Google Scholar
• Shi GH, Pisupati K, Parker JG, Corvari VJ, Payne CD, Xu W, Collins DS, Felippis MRD. Subcutaneous injection site pain of formulation matrices. Pharmaceut Res. 2021;38(5):779–93. doi:10.1007/s11095-021-03047-3. PMID: 33942212.
   PubMed Web of Science ®Google Scholar
• Ionova Y, Wilson L, Mallela KMG. Biologic excipients: importance of clinical awareness of inactive ingredients. Plos One. 2020;15(6):e0235076. doi:10.1371/journal.pone.0235076. PMID: 32584876.
   PubMed Web of Science ®Google Scholar
• Nash P, Vanhoof J, Hall S, Arulmani U, Tarzynski-Potempa R, Unnebrink K, Payne AN, Cividino A. Randomized crossover comparison of injection site pain with 40 mg/0.4 or 0.8 mL formulations of adalimumab in patients with rheumatoid arthritis. Rheumatol Ther. 2016;3(2):257–70. doi:10.1007/s40744-016-0041-3. PMID: 27747583.
   PubMed Web of Science ®Google Scholar
• Usach I, Martinez R, Festini T, Peris J-E. Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site. Adv Ther. 2019;36(11):2986–96. doi:10.1007/s12325-019-01101-6. PMID: 31587143.
   PubMed Web of Science ®Google Scholar
• Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJT. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010;9(4):325–38. doi:10.1038/nrd3003. PMID: 20305665.
   PubMed Web of Science ®Google Scholar
• Jiao Z, Wang G, Feng Z, Yan Z, Zhang J, Li G, Wang Q, Feng D. Safety profile of monoclonal antibody compared with traditional anticancer drugs: an analysis of Henan province spontaneous reporting system database. Front Pharmacol. 2022;12:760013. doi:10.3389/fphar.2021.760013. PMID: 35145400.
   PubMed Web of Science ®Google Scholar
• Li Y, Qi L, Bai H, Sun C, Xu S, Wang Y, Han C, Li Y, Liu L, Cheng X, et al. Safety, tolerability, pharmacokinetics, and immunogenicity of a monoclonal antibody (SCTA01) targeting SARS-CoV-2 in healthy adults: a randomized, double-blind, placebo-controlled, phase I study. Antimicrob Agents Ch. 2021;65(11):e01063–21. doi:10.1128/aac.01063-21. PMID: 34491805.
   Web of Science ®Google Scholar
• Hoe S, Boraey MA, Ivey JW, Finlay WH, Vehring R. Manufacturing and device options for the delivery of biotherapeutics. J Aerosol Med Pulm D. 2014;27(5):315–28. doi:10.1089/jamp.2013.1090. PMID: 24299502.
   PubMed Web of Science ®Google Scholar
• Keytruda [Package Insert], ORIG-1. 2014 [accessed 2022 Sep 23]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125514lbl.pdf.
   Google Scholar
• Keytruda [Package Insert], SUPPL-3. 2015 [accessed 2022 Sep 23]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125514s003lbl.pdf.
   Google Scholar
• Keytruda [Package Insert], SUPPL-67. 2019 [accessed 2022 Sep 23]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s067lbl.pdf.
   Google Scholar
• Fanelli JL. Injection: the third method of drug administration. Review of Optometry. 2012;149:32+.
   Google Scholar
• Dornbos BD, Moliterno CD. Injection procedures encountered in optometry [dissertation]. Big Rapids (MI): Ferris State University; 2012.
   Google Scholar
• Arivazhahan A. Introduction to basics of pharmacology and toxicology, volume 1: general and molecular pharmacology: principles of drug action. 2019. pp. 69–79. doi:10.1007/978-981-32-9779-1_4.
   Google Scholar
• U.S. Food and Drug Administration (FDA). Route of administration | FDA; 2017 [accessed 2022 Sep 27]. https://www.fda.gov/drugs/data-standards-manual-monographs/route-administration.
   Google Scholar
• Locke KW, Maneval DC, LaBarre MJ. ENHANZE® drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20. Drug Deliv. 2019;26(1):98–106. doi:10.1080/10717544.2018.1551442. PMID: 30744432.
   PubMed Web of Science ®Google Scholar
• Heo YA, Syed YY. Subcutaneous trastuzumab: a review in HER2-positive breast cancer. Target Oncol. 2019;14(6):749–58. doi:10.1007/s11523-019-00684-y. PMID: 31686307.
   PubMed Web of Science ®Google Scholar
• Villalba ML. Medical review; 2016 [accessed 2022 Apr 11]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761029Orig1s000MedR.pdf.
   Google Scholar
• Ribrag V, Dupuis J, Tilly H, Morschhauser F, Laine F, Houot R, Haioun C, Copie C, Varga A, Lambert J, et al. A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-hodgHodgkin lymphoma. Clin Cancer Res. 2014;20(1):213–20. doi:10.1158/1078-0432.ccr-13-0580. PMID: 24132920.
   PubMed Web of Science ®Google Scholar
• Jonaitis L, Marković S, Farkas K, Gheorghe L, Krznarić Ž, Salupere R, Mokricka V, Spassova Z, Gatev D, Grosu I, et al. Intravenous versus subcutaneous delivery of biotherapeutics in IBD: an expert’s and patient’s perspective. BMC Proc. 2021;15(S17):25. doi:10.1186/s12919-021-00230-7. PMID: 34879868.
   PubMedGoogle Scholar
• Falanga M, Canzona A, Mazzoni D. Preference for subcutaneous injection or intravenous infusion of biological therapy among Italian patients with SLE. J Patient Exp. 2019;6(1):41–45. doi:10.1177/2374373518770811. PMID: 31236450.
   PubMedGoogle Scholar
• Overton PM, Shalet N, Somers F, Allen JA. Patient preferences for subcutaneous versus intravenous administration of treatment for chronic immune system disorders: a systematic review. Patient Prefer Adher. 2021;15:811–34. doi:10.2147/ppa.s303279. PMID: 33907384.
   PubMed Web of Science ®Google Scholar
• Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006;11(1–2):81–88. doi:10.1016/s1359-6446(05)03638-x. PMID: 16478695.
   PubMed Web of Science ®Google Scholar
• Toutain PL, Bousquet‐mélou A. Plasma terminal half‐life. J Vet Pharmacol Ther. 2004;27(6):427–39. doi:10.1111/j.1365-2885.2004.00600.x. PMID: 15601438.
   PubMed Web of Science ®Google Scholar
• Birkett DJ. Pocket guide: pharmacokinetics made easy. Maidenhead, England: McGraw-Hill Education; 2009.
   Google Scholar
• Smith DA, Beaumont K, Maurer TS, Di L. Volume of distribution in drug design. J Med Chem. 2015;58(15):5691–98. doi:10.1021/acs.jmedchem.5b00201. PMID: 25799158.
   PubMed Web of Science ®Google Scholar
• Toutain PL, Bousquet-Mélou A. Bioavailability and its assessment. J Vet Pharmacol Ther. 2004;27(6):455–66. doi:10.1111/j.1365-2885.2004.00604.x. PMID: 15601440.
   PubMed Web of Science ®Google Scholar
• Kuna M, Mahdi F, Chade AR, Bidwell GL. Molecular size modulates pharmacokinetics, biodistribution, and renal deposition of the drug delivery biopolymer elastin-like polypeptide. Sci Rep-Uk. 2018;8(1):7923. doi:10.1038/s41598-018-24897-9. PMID: 29784932.
   PubMedGoogle Scholar
• Byers JP, Sarver JG. Chapter 10 - pharmacokinetic modeling. In: Hacker M, Messer W Bachmann K, editors. Pharmacology: principles and practice. San Diego: Academic Press; 2009. pp. 201–77. doi:10.1016/b978-0-12-369521-5.00010-5.
   Google Scholar
• Andrade C. The practical importance of half-life in psychopharmacology. J Clin Psychiatry. 2022;83:4. doi:10.4088/jcp.22f14584. PMID: 35900254.
   Web of Science ®Google Scholar
• Durairaj C, Shah JC, Senapati S, Kompella UB. Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure–pharmacokinetic relationships (QSPKR). Pharmaceut Res. 2008;26(5):1236. doi:10.1007/s11095-008-9728-7. PMID: 18841448.
   PubMed Web of Science ®Google Scholar
• Keizer RJ, Huitema ADR, Schellens JHM, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(8):493–507. doi:10.2165/11531280-000000000-00000. PMID: 20608753.
   PubMed Web of Science ®Google Scholar
• Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(10):633–59. doi:10.2165/11535960-000000000-00000. PMID: 20818831.
   PubMed Web of Science ®Google Scholar
• Dall’acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, Wu H, Kiener PA, Langermann S. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol. 2002;169(9):5171–80. doi:10.4049/jimmunol.169.9.5171. PMID: 12391234.
   PubMed Web of Science ®Google Scholar
• Vaccaro C, Bawdon R, Wanjie S, Ober RJ, Ward ES. Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies. Proc National Acad Sci. 2006;103(49):18709–14. doi:10.1073/pnas.0606304103. PMID: 17116867.
   PubMed Web of Science ®Google Scholar
• Wang W, Wang E, Balthasar J. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548–58. doi:10.1038/clpt.2008.170. PMID: 18784655.
   PubMed Web of Science ®Google Scholar
• Gibson JG, Evans WA. Clinical studies of the blood volume. II. The relation of plasma and total blood volume to venous pressure, blood velocity rate, physical measurements, age and sex in ninety normal humans. J Clin Invest. 1937;16(3):317–28. doi:10.1172/jci100860. PMID: 16694481.
   PubMedGoogle Scholar
• Gibaldi M, McNamara PJ. Apparent volumes of distribution and drug binding to plasma proteins and tissues. Eur J Clin Pharmacol. 1978;13(5):373–78. doi:10.1007/bf00644611. PMID: 668796.
   PubMed Web of Science ®Google Scholar
• Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. Cpt Pharmacometrics Syst Pharmacol. 2017;6(9):576–88. doi:10.1002/psp4.12224. PMID: 28653357.
   PubMedGoogle Scholar
• Bookbinder LH, Hofer A, Haller MF, Zepeda ML, Keller G-A, Lim JE, Edgington TS, Shepard HM, Patton JS, Frost GI. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release. 2006;114(2):230–41. doi:10.1016/j.jconrel.2006.05.027. PMID: 16876899.
   PubMed Web of Science ®Google Scholar
• Sime FB, Roberts MS, Roberts JA. Optimization of dosing regimens and dosing in special populations. Clin Microbiol Infec. 2015;21(10):886–93. doi:10.1016/j.cmi.2015.05.002. PMID: 25980350.
   PubMed Web of Science ®Google Scholar
• Tabrizi M, Neupane D, Elie SE, Shankaran H, Juan V, Zhang S, Hseih S, Fayadat-Dilman L, Zhang D, Song Y, et al. Pharmacokinetic properties of humanized IgG1 and IgG4 antibodies in preclinical species: translational evaluation. Aaps J. 2019;21(3):39. doi:10.1208/s12248-019-0304-3. PMID: 30868312.
   PubMed Web of Science ®Google Scholar
• Wang W, Prueksaritanont T. Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited. Biopharm Drug Dispos. 2010;31:253–63. doi:10.1002/bdd.708. PMID: 20437464.
   PubMed Web of Science ®Google Scholar
• Igawa T, Tsunoda H, Tachibana T, Maeda A, Mimoto F, Moriyama C, Nanami M, Sekimori Y, Nabuchi Y, Aso Y, et al. Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel. 2010;23(5):385–92. doi:10.1093/protein/gzq009. PMID: 20159773.
   PubMed Web of Science ®Google Scholar
• Yang D, Kroe-Barrett R, Singh S, Laue T. IgG charge: practical and biological implications. Antibodies. 2019;8(1):24. doi:10.3390/antib8010024. PMID: 31544830.
   Web of Science ®Google Scholar
• Piche-Nicholas NM, Avery LB, King AC, Kavosi M, Wang M, O’hara DM, Tchistiakova L, Katragadda M. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics. Mabs. 2018;10(1):81–94. doi:10.1080/19420862.2017.1389355. PMID: 28991504.
   PubMed Web of Science ®Google Scholar
• Boswell CA, Tesar DB, Mukhyala K, Theil FP, Fielder PJ, Khawli LA. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjugate Chem. 2010;21(12):2153–63. doi:10.1021/bc100261d. PMID: 21053952.
   PubMed Web of Science ®Google Scholar
• Yadav DB, Sharma VK, Boswell CA, Hotzel I, Tesar D, Shang Y, Ying Y, Fischer SK, Grogan JL, Chiang EY, et al. Evaluating the use of antibody variable region (Fv) charge as a risk assessment tool for predicting typical cynomolgus monkey pharmacokinetics*. J Biol Chem. 2015;290(50):29732–41. doi:10.1074/jbc.m115.692434. PMID: 26491012.
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Thangaraju A, Leung D, Tang Y, Witcher DR, Lu J, Wroblewski VJ. Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics. Mabs. 2015;7(3):483–93. doi:10.1080/19420862.2015.1016696. PMID: 25695748.
   PubMed Web of Science ®Google Scholar
• Kingsbury JS, Saini A, Auclair SM, Fu L, Lantz MM, Halloran KT, Calero-Rubio C, Schwenger W, Airiau CY, Zhang J, et al. A single molecular descriptor to predict solution behavior of therapeutic antibodies. Sci Adv. 2020;6(32):eabb0372. doi:10.1126/sciadv.abb0372. PMID: 32923611.
   PubMed Web of Science ®Google Scholar
• Khawli LA, Glasky MS, Alauddin MM, Epstein AL. Improved tumor localization and radioimaging with chemically modified monoclonal antibodies. Cancer Biotherapy Radiopharm. 1996;11(3):203–15. doi:10.1089/cbr.1996.11.203. PMID: 10851539.
   PubMed Web of Science ®Google Scholar
• Li L, Kumar S, Buck PM, Burns C, Lavoie J, Singh SK, Warne NW, Nichols P, Luksha N, Boardman D. Concentration dependent viscosity of monoclonal antibody solutions: explaining experimental behavior in terms of molecular properties. Pharmaceut Res. 2014;31(11):3161–78. doi:10.1007/s11095-014-1409-0. PMID: 24906598.
   PubMed Web of Science ®Google Scholar
• Sharma VK, Patapoff TW, Kabakoff B, Pai S, Hilario E, Zhang B, Li C, Borisov O, Kelley RF, Chorny I, et al. In silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability. Proc National Acad Sci. 2014;111(52):18601–06. doi:10.1073/pnas.1421779112. PMID: 25512516.
   PubMed Web of Science ®Google Scholar
• Strickley RG, Lambert WJ. A review of formulations of commercially available antibodies. J Pharm Sci. 2021;110(7):e56. doi:10.1016/j.xphs.2021.03.017. PMID: 33789155.
   Web of Science ®Google Scholar
• Garidel P, Blume A, Wagner M. Prediction of colloidal stability of high concentration protein formulations. Pharm Dev Technol. 2014;20(3):367–74. doi:10.3109/10837450.2013.871032. PMID: 24392929.
   PubMed Web of Science ®Google Scholar
• Sun MF, Liao JN, Jing ZY, Gao H, Shen BB, Y-F X, Fang WJ. Effects of polyol excipient stability during storage and use on the quality of biopharmaceutical formulations. J Pharm Analysis. 2022;12(5):774–82. doi:10.1016/j.jpha.2022.03.003.
   PubMed Web of Science ®Google Scholar
• James S, McManus JJ. Thermal and solution stability of lysozyme in the presence of sucrose, glucose, and trehalose. J Phys Chem B. 2012;116(34):10182–88. doi:10.1021/jp303898g. PMID: 22909409.
   PubMed Web of Science ®Google Scholar
• Gervasi V, Agnol RD, Cullen S, McCoy T, Vucen S, Crean A. Parenteral protein formulations: an overview of approved products within the European union. Eur J Pharm Biopharm. 2018;131:8–24. doi:10.1016/j.ejpb.2018.07.011. PMID: 30006246.
   PubMed Web of Science ®Google Scholar
• Liu GY, Nie S, Zheng X, Li N. Activity-based protein profiling probe for the detection of enzymes catalyzing polysorbate degradation. Anal Chem. 2022;94(24):8625–32. doi:10.1021/acs.analchem.2c00059.
   PubMed Web of Science ®Google Scholar
• Jones MT, Mahler HC, Yadav S, Bindra D, Corvari V, Fesinmeyer RM, Gupta K, Harmon AM, Hinds KD, Koulov A, et al. Considerations for the use of polysorbates in biopharmaceuticals. Pharmaceut Res. 2018;35(8):148. doi:10.1007/s11095-018-2430-5. PMID: 29797101.
   PubMed Web of Science ®Google Scholar
• Dwivedi M, Blech M, Presser I, Garidel P. Polysorbate degradation in biotherapeutic formulations: identification and discussion of current root causes. Int J Pharmaceut. 2018;552(1–2):422–36. doi:10.1016/j.ijpharm.2018.10.008. PMID: 30300706.
   PubMed Web of Science ®Google Scholar
• Singh SK, Kolhe P, Mehta AP, Chico SC, Lary AL, Huang M. Frozen state storage instability of a monoclonal antibody: aggregation as a consequence of trehalose crystallization and protein unfolding. Pharmaceut Res. 2011;28(4):873–85. doi:10.1007/s11095-010-0343-z. PMID: 21213025.
   PubMed Web of Science ®Google Scholar
• Wang W, Singh S, Zeng DL, King K, Nema S. Antibody structure, instability, and formulation. J Pharm Sci. 2007;96(1):1–26. doi:10.1002/jps.20727. PMID: 16998873.
   PubMed Web of Science ®Google Scholar
• Neergaard MS, Nielsen AD, Parshad H, Weert MVD. Stability of monoclonal antibodies at high‐Concentration: head‐to‐head comparison of the IgG1 and IgG4 subclass. J Pharm Sci. 2014;103(1):115–27. doi:10.1002/jps.23788. PMID: 24282022.
   PubMed Web of Science ®Google Scholar
• Garidel P, Kuhn AB, Schäfer LV, Karow-Zwick AR, Blech M. High-concentration protein formulations: how high is high? Eur J Pharm Biopharm. 2017;119:353–60. doi:10.1016/j.ejpb.2017.06.029. PMID: 28690199.
   PubMed Web of Science ®Google Scholar
• Agrawal NJ, Helk B, Kumar S, Mody N, Sathish HA, Samra HS, Buck PM, Li L, Trout BL. Computational tool for the early screening of monoclonal antibodies for their viscosities. Mabs. 2016;8(1):43–48. doi:10.1080/19420862.2015.1099773. PMID: 26399600.
   PubMed Web of Science ®Google Scholar
• Neergaard MS, Kalonia DS, Parshad H, Nielsen AD, Møller EH, van de WM. Viscosity of high concentration protein formulations of monoclonal antibodies of the IgG1 and IgG4 subclass – prediction of viscosity through protein–protein interaction measurements. Eur J Pharm Sci. 2013;49(3):400–10. doi:10.1016/j.ejps.2013.04.019. PMID: 23624326.
   PubMed Web of Science ®Google Scholar
• Wang S, Zhang N, Hu T, Dai W, Feng X, Zhang X, Qian F. Viscosity-lowering effect of amino acids and salts on highly concentrated solutions of two IgG1 monoclonal antibodies. Mol Pharmaceut. 2015;12(12):4478–87. doi:10.1021/acs.molpharmaceut.5b00643. PMID: 26528726.
   PubMed Web of Science ®Google Scholar
• Nichols P, Li L, Kumar S, Buck PM, Singh SK, Goswami S, Balthazor B, Conley TR, Sek D, Allen MJ. Rational design of viscosity reducing mutants of a monoclonal antibody: hydrophobic versus electrostatic inter-molecular interactions. Mabs. 2015;7(1):212–30. doi:10.4161/19420862.2014.985504. PMID: 25559441.
   PubMed Web of Science ®Google Scholar
• Wang W. Advanced protein formulations. Protein Sci. 2015;24:1031–39. doi:10.1002/pro.2684. PMID: 25858529.
   PubMed Web of Science ®Google Scholar
• Warne NW. Development of high concentration protein biopharmaceuticals: the use of platform approaches in formulation development. Eur J Pharm Biopharm. 2011;78(2):208–12. doi:10.1016/j.ejpb.2011.03.004. PMID: 21406226.
   PubMed Web of Science ®Google Scholar
• Gupta P, Makowski EK, Kumar S, Zhang Y, Scheer JM, Tessier PM. Antibodies with weakly basic isoelectric points minimize trade-offs between formulation and physiological colloidal properties. Mol Pharmaceut. 2021;19(3):775–87. doi:10.1021/acs.molpharmaceut.1c00373.
   Web of Science ®Google Scholar
• Jäger S, Wagner TR, Rasche N, Kolmar H, Hecht S, Schröter C. Generation and biological evaluation of Fc antigen binding fragment-drug conjugates as a novel antibody-based format for targeted drug delivery. Bioconjugate Chem. 2021;32(8):1699–710. doi:10.1021/acs.bioconjchem.1c00240. PMID: 34185508.
   PubMed Web of Science ®Google Scholar
• Murer P, Neri D. Antibody-cytokine fusion proteins: a novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation. New Biotechnol. 2019;52:42–53. doi:10.1016/j.nbt.2019.04.002. PMID: 30991144.
   PubMed Web of Science ®Google Scholar
• Egan TJ, Diem D, Weldon R, Neumann T, Meyer S, Urech DM. Novel multispecific heterodimeric antibody format allowing modular assembly of variable domain fragments. Mabs. 2017;9(1):68–84. doi:10.1080/19420862.2016.1248012. PMID: 27786600.
   PubMed Web of Science ®Google Scholar
• Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov. 2002;1(6):457–62. doi:10.1038/nrd818. PMID: 12119747.
   PubMed Web of Science ®Google Scholar
• Deehan M, Garcês S, Kramer D, Baker MP, Rat D, Roettger Y, Kromminga A. Managing unwanted immunogenicity of biologicals. Autoimmun Rev. 2015;14(7):569–74. doi:10.1016/j.autrev.2015.02.007. PMID: 25742758.
   PubMed Web of Science ®Google Scholar
• Johnson DE. Biotherapeutics: challenges and opportunities for predictive toxicology of monoclonal antibodies. Int J Mol Sci. 2018;19(11):3685. doi:10.3390/ijms19113685. PMID: 30469350.
   PubMed Web of Science ®Google Scholar
• Gorovits B, Clements-Egan A, Birchler M, Liang M, Myler H, Peng K, Purushothama S, Rajadhyaksha M, Salazar-Fontana L, Sung C, et al. Pre-existing antibody: biotherapeutic modality-based review. Aaps J. 2016;18(2):311–20. doi:10.1208/s12248-016-9878-1. PMID: 26821802.
   PubMed Web of Science ®Google Scholar
• Knezevic I, Griffiths E. WHO standards for biotherapeutics, including biosimilars: an example of the evaluation of complex biological products. Ann Ny Acad Sci. 2018;1407(1):5–16. doi:10.1111/nyas.13434. PMID: 28905423.
   Web of Science ®Google Scholar
• Mehta MU, Uppoor RS, Conner DP, Seo P, Vaidyanathan J, Volpe DA, Stier E, Chilukuri D, Dorantes A, Ghosh T, et al. Impact of the US FDA “biopharmaceutics classification system” (BCS) guidance on global drug development. Mol Pharmaceut. 2017;14(12):4334–38. doi:10.1021/acs.molpharmaceut.7b00687. PMID: 29076742.
   PubMed Web of Science ®Google Scholar
• Darrow JJ, Avorn J, Kesselheim AS. FDA approval and regulation of pharmaceuticals, 1983-2018. Jama. 2020;323(2):164–76. doi:10.1001/jama.2019.20288. PMID: 31935033.
   PubMed Web of Science ®Google Scholar
• Ishii-Watabe A, Shibata H, Nishimura K, Hosogi J, Aoyama M, Nishimiya K, Saito Y. Immunogenicity of therapeutic protein products: current considerations for anti-drug antibody assay in Japan. Bioanalysis. 2017;10(2):95–105. doi:10.4155/bio-2017-0186. PMID: 29243491.
   PubMed Web of Science ®Google Scholar
• Downing NS, Aminawung JA, Shah ND, Krumholz HM, Ross JS. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. Jama. 2014;311(4):368–77. doi:10.1001/jama.2013.282034. PMID: 24449315.
   PubMed Web of Science ®Google Scholar
• Dreher-Lesnick SM, Stibitz S, Carlson PE, Britton RA, Cani PD. U.S. regulatory considerations for development of live biotherapeutic products as drugs. Microbiol Spectr. 2017;5:5. doi:10.1128/microbiolspec.bad-0017-2017. PMID: 28975881.
   Web of Science ®Google Scholar
• Hung JJ, Dear BJ, Dinin AK, Borwankar AU, Mehta SK, Truskett TT, Johnston KP. Improving viscosity and stability of a highly concentrated monoclonal antibody solution with concentrated proline. Pharmaceut Res. 2018;35(7):133. doi:10.1007/s11095-018-2398-1. PMID: 29713822.
   PubMed Web of Science ®Google Scholar
• Rodrigues D, Tanenbaum LM, Thirumangalathu R, Somani S, Zhang K, Kumar V, Amin K, Thakkar SV. Product-specific impact of viscosity modulating formulation excipients during ultra-high concentration biotherapeutics drug product development. J Pharm Sci. 2021;110(3):1077–82. doi:10.1016/j.xphs.2020.12.016. PMID: 33340533.
   PubMed Web of Science ®Google Scholar
• Kumar S, Singh SK. Developability of biotherapeutics: computational approaches. 1st ed. Boca Raton (FL): CRC Press; 2015.
   Google Scholar
• Ahmed L, Gupta P, Martin KP, Scheer JM, Nixon AE, Kumar S. Intrinsic physicochemical profile of marketed antibody-based biotherapeutics. P Natl Acad Sci USA. 2021;118(37):e2020577118. doi:10.1073/pnas.2020577118. PMID: 34504010.
   PubMed Web of Science ®Google Scholar
• Prabakaran R, Rawat P, Kumar S, Gromiha MM. Evaluation of in silico tools for the prediction of protein and peptide aggregation on diverse datasets. Brief Bioinform. 2021;22(6): PMID: 34181000. doi:10.1093/bib/bbab240.
   PubMed Web of Science ®Google Scholar
• Liu Y, Tsang K, Mays M, Hansen G, Chiecko J, Crames M, Wei Y, Zhou W, Fredrick C, Hu J, et al. An adapted consensus protein design strategy for identifying globally optimal biotherapeutics. Mabs. 2022;14(1):2073632. doi:10.1080/19420862.2022.2073632. PMID: 35613320.
   PubMed Web of Science ®Google Scholar
• Lin J, Lee SL, Russell AM, Huang RF, Batt MA, Chang SS, Ferrante A, Verdino P, Henry KA. A structure-based engineering approach to abrogate pre-existing antibody binding to biotherapeutics. Plos One. 2021;16(7):e0254944. doi:10.1371/journal.pone.0254944. PMID: 34297759.
   PubMed Web of Science ®Google Scholar
• Narayanan H, Dingfelder F, Butté A, Lorenzen N, Sokolov M, Arosio P. Machine learning for biologics: opportunities for protein engineering, developability, and formulation. Trends Pharmacol Sci. 2021;42(3):151–65. doi:10.1016/j.tips.2020.12.004. PMID: 33500170.
   PubMed Web of Science ®Google Scholar
• The Antibody Society. Therapeutic monoclonal antibodies approved or in review in the EU or US; 2022 [accessed 2022 Feb 9]. www.antibodysociety.org.
   Google Scholar
• Clinical Trials. 2022 [accessed 2022 Feb 9]. https://clinicaltrials.gov/.
   Google Scholar
• Lefranc MP. IMGT, the international ImMunoGeneTics information system. Cold Spring Harb Protoc. 2011;2011(6):db.top115. doi:10.1101/pdb.top115. PMID: 21632786.
   Google Scholar
• Lefranc MP, Giudicelli V, Duroux P, Jabado-Michaloud J, Folch G, Aouinti S, Carillon E, Duvergey H, Houles A, Paysan-Lafosse T, et al. IMGT®, the international ImMunoGeneTics information system® 25 years on. Nucleic Acids Res. 2015;43(D1):D413–22. doi:10.1093/nar/gku1056. PMID: 25378316.
   PubMed Web of Science ®Google Scholar
• Craic. Therapeutic antibody database; 2022 [accessed 2022 Feb 8]. https://tabs.craic.com.
   Google Scholar
• Ye J, Ma N, Madden TL, Ostell JM. IgBLAST: an immunoglobulin variable domain sequence analysis tool. Nucleic Acids Res. 2013;41:W34–40. doi:10.1093/nar/gkt382. PMID: 23671333.
   PubMed Web of Science ®Google Scholar
• Molecular Operating Environment (MOE). Chemical computing group ULC; 2022 [accessed 2023 Feb 15]. https://www.chemcomp.com/.
   Google Scholar